FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165146762> ?p ?o ?g. }

• W2165146762 abstract "Cancer immunotherapy, i.e. activation of the patient’s own immune system to combat cancer, represents a treatment strategy which is being clinically tested to complement surgery, radiotherapy and chemotherapy – the current cornerstones of our fight against cancer. It has become clear now, that tumors not only escape immune recognition but also actively suppress antitumor immune responses. Cancer immunotherapy therefore has to overcome several obstacles. Since the immune system has evolved to fight infections there are intrinsic mechanisms that limit the ability to react against self antigens. If however, antitumor immune responses are generated, the genetic instability of tumor cells and the immunosuppressive state of the tumor microenvironment create a second barrier that hampers immune mediated tumor eradication. In order to improve cancer immunotherapy, effective manipulation of the immune system to break self-tolerance need to be designed and approaches that counteract immunosuppressive mechanisms need to be developed. We show that treatment with tumor-specific phage display particles leads to eradication of established mouse melanoma tumors and long-term survival. The effect is initiated by tumor associated macrophages (TAMs), which after bacteriophage encounter reverse their typical immunosuppressive state and create an environment that promotes recruitment of neutrophils and potentiates neutrophil-mediated tumor destruction. The pro-tumorigenic phenotype of prostate cancer-TAMs can be also modified using zoledronic acid (ZA). We show that ZA suppresses the expression of MMP-9 by TAMs and, in combination with IL-12, enhances their tumor-eliminating functions. Furthermore, ZA drives the proliferation and activation of T cells which lyse ZA-pulsed prostate cancer cells. Finally, we developed a more clinically suitable protocol for delivery of DNA vaccines using electroporation. Shortening of electroporation pulse intervals, resulting in a 10-fold reduction of total pulse length, and application of local anesthesia do not negatively affect the vigor of antigenspecific cytotoxic T lymphocytes responses normally observed after DNA electrovaccination. This study has contributed to the identification and development of novel immunotherapeutic approaches which have a significant potential for use in cancer immunotherapy. List of publications I. Eriksson F, Culp WD, Massey R, Egevad L, Garland D, Persson MAA, Pisa P. Tumor specific phage particles promote tumor regression in a mouse melanoma model. Cancer Immunology Immunotherapy, 2007, May; 56(5): 677-687 II. Eriksson F, Tsagozis P, Persson MAA, Harris RA and Pisa P. Tumor-specific bacteriophages induce tumor destruction through activation of tumor associated macrophages. (Manuscript submitted) III. Tsagozis P, Eriksson F, Pisa P. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunology Immunotherapy, 2008, In press IV. Roos A-K *, Eriksson F *, Pisa P, King AD. Optimization of skin electroporation to increase tolerability of DNA vaccine delivery to patients. (Manuscript submitted) * Shared first authorship Table of contents" @default.
• W2165146762 created "2016-06-24" @default.
• W2165146762 creator A5055160032 @default.
• W2165146762 date "2008-05-22" @default.
• W2165146762 modified "2023-09-28" @default.
• W2165146762 title "Novel approaches for cancer immunotherapy" @default.
• W2165146762 cites W1480318795 @default.
• W2165146762 cites W1480357432 @default.
• W2165146762 cites W1483194800 @default.
• W2165146762 cites W1488482313 @default.
• W2165146762 cites W1488530423 @default.
• W2165146762 cites W1496905172 @default.
• W2165146762 cites W1498187417 @default.
• W2165146762 cites W1505248622 @default.
• W2165146762 cites W1510865194 @default.
• W2165146762 cites W1519513582 @default.
• W2165146762 cites W1521418395 @default.
• W2165146762 cites W1525556816 @default.
• W2165146762 cites W1548322053 @default.
• W2165146762 cites W1549471106 @default.
• W2165146762 cites W1556274289 @default.
• W2165146762 cites W1559937222 @default.
• W2165146762 cites W1562210554 @default.
• W2165146762 cites W1563631631 @default.
• W2165146762 cites W1573470869 @default.
• W2165146762 cites W1587050401 @default.
• W2165146762 cites W1591942886 @default.
• W2165146762 cites W1597610606 @default.
• W2165146762 cites W1603510059 @default.
• W2165146762 cites W1604693296 @default.
• W2165146762 cites W1606386817 @default.
• W2165146762 cites W1621209507 @default.
• W2165146762 cites W1636670860 @default.
• W2165146762 cites W1642873092 @default.
• W2165146762 cites W1653792548 @default.
• W2165146762 cites W1669165205 @default.
• W2165146762 cites W1677573439 @default.
• W2165146762 cites W1754072307 @default.
• W2165146762 cites W1774815589 @default.
• W2165146762 cites W1826859465 @default.
• W2165146762 cites W1850539057 @default.
• W2165146762 cites W1878591306 @default.
• W2165146762 cites W1892560324 @default.
• W2165146762 cites W1905974666 @default.
• W2165146762 cites W1917962573 @default.
• W2165146762 cites W1920268203 @default.
• W2165146762 cites W1963592300 @default.
• W2165146762 cites W1964321121 @default.
• W2165146762 cites W1964612175 @default.
• W2165146762 cites W1964780815 @default.
• W2165146762 cites W1965037168 @default.
• W2165146762 cites W1965529336 @default.
• W2165146762 cites W1968694633 @default.
• W2165146762 cites W1971026687 @default.
• W2165146762 cites W1973081965 @default.
• W2165146762 cites W1973251492 @default.
• W2165146762 cites W1975747378 @default.
• W2165146762 cites W1977009116 @default.
• W2165146762 cites W1977340233 @default.
• W2165146762 cites W1980690619 @default.
• W2165146762 cites W1981087308 @default.
• W2165146762 cites W1981182552 @default.
• W2165146762 cites W1984451487 @default.
• W2165146762 cites W1984690727 @default.
• W2165146762 cites W1985774274 @default.
• W2165146762 cites W1987591286 @default.
• W2165146762 cites W1988258076 @default.
• W2165146762 cites W1988437817 @default.
• W2165146762 cites W1989305940 @default.
• W2165146762 cites W1989911648 @default.
• W2165146762 cites W1990626857 @default.
• W2165146762 cites W1991464867 @default.
• W2165146762 cites W1991629081 @default.
• W2165146762 cites W1991652096 @default.
• W2165146762 cites W1992699637 @default.
• W2165146762 cites W1992700503 @default.
• W2165146762 cites W1992921552 @default.
• W2165146762 cites W1993051112 @default.
• W2165146762 cites W1994003134 @default.
• W2165146762 cites W1995570137 @default.
• W2165146762 cites W1995805772 @default.
• W2165146762 cites W1995927503 @default.
• W2165146762 cites W1996120942 @default.
• W2165146762 cites W1996382553 @default.
• W2165146762 cites W1998297552 @default.
• W2165146762 cites W1999355517 @default.
• W2165146762 cites W1999625461 @default.
• W2165146762 cites W1999936841 @default.
• W2165146762 cites W2000801994 @default.
• W2165146762 cites W2001604427 @default.
• W2165146762 cites W2001717792 @default.
• W2165146762 cites W2001737701 @default.
• W2165146762 cites W2001848039 @default.
• W2165146762 cites W2001956357 @default.
• W2165146762 cites W2001998219 @default.
• W2165146762 cites W2003692790 @default.
• W2165146762 cites W2008243630 @default.
• W2165146762 cites W2008355513 @default.
• W2165146762 cites W2009016792 @default.
• W2165146762 cites W2009644962 @default.

• next